Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 5, 2012, Pages 714-724

  Azuma, Yuichiro ^a,e   Hata, Kojiro ^b   Sai, Kimie ^a   Udagawa, Ryoko ^b   Hirakawa, Akihiro ^c   Tohkin, Masahiro ^a,f   Ryushima, Yasuaki ^b   Makino, Yoshinori ^b   Yokote, Nobuaki ^b   Morikawa, Norifumi ^d   Fujiwara, Yasuhiro ^b   Saito, Yoshiro ^a   Yamamoto, Hiroshi ^b  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^f NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Capecitabine; Efficacy; Electronic medical record; Hand foot syndrome

Indexed keywords

CAPECITABINE; CARBOHYDRATE ANTIGEN 15-3; CARCINOEMBRYONIC ANTIGEN; IRINOTECAN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PRODRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; STOMATITIS; TREATMENT DURATION; BLOOD; BREAST TUMOR; CONFIDENCE INTERVAL; FEMALE; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PRODRUGS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84861209515     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.717     Document Type: Article

References (23)

1. Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opin. Drug Saf., 9, 831-841 (2010).
2. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34, 1274-1281 (1998).
3. Saif MW. Capecitabine and hand-foot syndrome. Expert Opin. Drug Saf., 10, 159-169 (2011).
4. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol., 45, 291-297 (2000).
5. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med., 352, 2696-2704 (2005).
6. Twelves C, Gollins S, Grieve R, Samuel L. A randomised crossover trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann. Oncol., 17, 239-245 (2006).
7. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin. Colorectal Cancer, 6, 278-287 (2006).
8. Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist, 12, 1178-1182 (2007).
9. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist, 13, 1001-1011 (2008).
10. Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, Martinelli E, Ciardiello F. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol. Rep., 21, 1023-1028 (2009).
11. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 15, 85-92 (2010).
12. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J. Exp. Clin. Cancer Res., 29, 95 (2010).
13. Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Giessen C, Moosmann N, Heinemann V. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br. J. Cancer, 105, 206-211 (2011).
14. Tsuyuki S, Kawaguchisakita N, Tsubota Y, Ukikusa M, Kohno Y. More effective positioning of capecitabine for advanced and metastatic breast cancer. Gan To Kagaku Ryoho, 37, 649-653 (2010).
15. Osako T, Ito Y, Ushijima M, Takahashi S, Tokudome N, Sugihara T, Iwase T, Matsuura M, Hatake K. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. Cancer Chemother. Pharmacol., 63, 865-871 (2009).
16. Andreetta C, Puppin C, Minisini A, Valent F, Pegolo E, Damante G, Di Loreto C, Pizzolitto S, Pandolfi M, Fasola G, Piga A, Puglisi F. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann. Oncol., 20, 265-271 (2009).
17. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL, Capecitabine Colorectal Cancer Study Group. Firstline oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann. Oncol., 13, 566-575 (2002).
18. Leonard R, O'Shaughnessy J, Vukelja S, Gorbounova V, Chan-Navarro CA, Maraninchi D, Barak-Wigler N, McKendrick JJ, Harker WG, Bexon AS, Twelves C. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann. Oncol., 17, 1379-1385 (2006).
19. Milano G, Etienne-Grimaldi MC, Mari M, Lassalle S, Formento JL, Francoual M, Lacour JP, Hofman P. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br. J. Clin. Pharmacol., 66, 88-95 (2008).
20. Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin. Colorectal Cancer, 6, 219-223 (2006).
21. Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J. Cancer Res. Clin. Oncol., 137, 953-957 (2011).
22. Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita G, Díaz-Rubio E, Benítez J, González-Neira A. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin. Cancer Res., 17, 2006-2013 (2011).
23. Ribelles N, López-Siles J, Sánchez A, González E, Sánchez MJ, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba E. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr. Drug Metab., 9, 336-343 (2008).